QT Imaging Doubles Revenue, Expands Commercial Footprint Amid Breast Imaging Shift
Event summary
- QT Imaging reported $14M in H1 2026 revenue, up 116% YoY, shipping 28 Breast Acoustic CT scanners.
- Company secured FDA clearances for enhanced scanner configuration and software functionality.
- Successfully completed first routine FDA inspection with zero Form 483 observations.
- Expanded international presence with regulatory authorizations in Saudi Arabia, UAE, and Israel.
- American Medical Association approved Category III CPT code for QT Imaging's service, effective January 2027.
The big picture
QT Imaging's strong H1 2026 performance reflects the growing demand for radiation-free, quantitative breast imaging solutions. The company's strategic focus on expanding its commercial footprint, strengthening its clinical evidence base, and securing regulatory approvals positions it to capitalize on the shift toward more personalized and data-driven breast health management. With the new CPT code in place, QT Imaging is well-positioned to accelerate its U.S. adoption and drive long-term growth.
What we're watching
- Commercial Scaling
- Whether QT Imaging can sustain its rapid commercial expansion while maintaining operational discipline.
- Regulatory Momentum
- The pace at which QT Imaging secures additional international regulatory authorizations.
- Reimbursement Pathway
- How the new CPT code will impact QT Imaging's reimbursement strategy and U.S. adoption.